Anbio Biotechnology (NNNN) Accumulated Expenses (2023 - 2025)

Anbio Biotechnology's Accumulated Expenses history runs 3 years deep, the most recent figure standing at $87836.0 for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 16.33% year-over-year to $87836.0; the TTM figure through Dec 2025 stood at $87836.0 (down 16.33% YoY), while the FY2025 annual figure was $87836.0, down 16.33% from the prior year.
• Accumulated Expenses was $87836.0 for Q4 2025 at Anbio Biotechnology, down from $104979.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $130967.0 in Q4 2023 to a low of $87836.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $107927.3 across 3 years, with a median of $104979.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses declined 19.84% in 2024, then decreased 16.33% in 2025.
• A 3-year view of Accumulated Expenses shows it stood at $130967.0 in 2023, then decreased by 19.84% to $104979.0 in 2024, then retreated by 16.33% to $87836.0 in 2025.
• The last three Accumulated Expenses figures came in at $87836.0 (Q4 2025), $104979.0 (Q4 2024), and $130967.0 (Q4 2023), per Business Quant data.